Introduction {#acn3364-sec-0005}
============

In the absence of sufficiently detailed insights into the pathophysiology of epilepsy,[1](#acn3364-bib-0001){ref-type="ref"} development of anticonvulsant therapies has relied on empirical drug screening efforts. Decades of screening and subsequent drug development have produced many new anticonvulsants, yet, epilepsy remains medically intractable in one‐third of patients.[2](#acn3364-bib-0002){ref-type="ref"} Recently, it has been proposed that this lack of progress is a consequence of the method by which compounds are screened.[3](#acn3364-bib-0003){ref-type="ref"}, [4](#acn3364-bib-0004){ref-type="ref"} To date, initial screening is based on acute application of convulsant conditions to normal brain tissue,[2](#acn3364-bib-0002){ref-type="ref"}, [4](#acn3364-bib-0004){ref-type="ref"} but this produces patterns of epileptic activity that are substantially different from spontaneous epileptiform activity in chronically epileptic brain tissue.[5](#acn3364-bib-0005){ref-type="ref"} Thus, we considered the hypothesis that screening for anticonvulsants in chronically epileptic tissue would uncover agents that may be uniquely effective in medically intractable epilepsy.[6](#acn3364-bib-0006){ref-type="ref"}

Unfortunately, most epileptiform activity in chronically epileptic brain is comprised of brief interictal electrographic spikes. While not benign,[7](#acn3364-bib-0007){ref-type="ref"} spikes are not the target of anticonvulsants.[8](#acn3364-bib-0008){ref-type="ref"} Actual seizure activity in experimental epilepsy is rare, unpredictable, and develops slowly after an inciting brain injury.[9](#acn3364-bib-0009){ref-type="ref"} Morbidity and mortality are significant once seizure frequencies are sufficiently high for screening studies.[10](#acn3364-bib-0010){ref-type="ref"} At all seizure frequencies, clustering of seizures substantially increases the sampling required to discern anticonvulsant effects.[11](#acn3364-bib-0011){ref-type="ref"} Thus, in vivo models of chronic seizures have not been practical for drug screening. Accordingly, we developed a staged screening program in which initial evaluations are based on spontaneous seizures in a chronically epileptic in vitro preparation in which these practical shortcomings are obviated.

Organotypic hippocampal slice cultures[12](#acn3364-bib-0012){ref-type="ref"} preserve the key circuitry of the in vivo hippocampus.[13](#acn3364-bib-0013){ref-type="ref"} However, brain slice preparation involves massive traumatic axotomy at the cut surfaces, so that the slice can be considered a model of severe traumatic sheer injury and an in vitro extension of the undercut cortical model of posttraumatic epilepsy.[14](#acn3364-bib-0014){ref-type="ref"} As a consequence of the deafferentation, robust sprouting takes place,[15](#acn3364-bib-0015){ref-type="ref"}, [16](#acn3364-bib-0016){ref-type="ref"} so that connectivity between pyramidal cells increases from 3% in acute slices to 30% in organotypic slices.[17](#acn3364-bib-0017){ref-type="ref"}, [18](#acn3364-bib-0018){ref-type="ref"} In light of this abundant reciprocal excitation, it is not surprising that organotypic slice cultures are hyperexcitable[19](#acn3364-bib-0019){ref-type="ref"} and even spontaneously epileptic[20](#acn3364-bib-0020){ref-type="ref"}, [21](#acn3364-bib-0021){ref-type="ref"} (see Heinemann and Staley[22](#acn3364-bib-0022){ref-type="ref"} for review). We have characterized epileptogenesis in this preparation.[23](#acn3364-bib-0023){ref-type="ref"}, [24](#acn3364-bib-0024){ref-type="ref"} Increases in extracellular lactate accompanied seizures in human hippocampus,[25](#acn3364-bib-0025){ref-type="ref"}, [26](#acn3364-bib-0026){ref-type="ref"} and we found that lactate production was correlated with seizure‐like activity in organotypic cultures. Lactate dehydrogenase (LDH) is released into culture medium after plasma membrane loses its integrity,[27](#acn3364-bib-0027){ref-type="ref"}, [28](#acn3364-bib-0028){ref-type="ref"}, [29](#acn3364-bib-0029){ref-type="ref"} and its concentration is correlated with cell death in cultures. We then demonstrated that this preparation and lactate and LDH assays can be used to evaluate anticonvulsant efficacy, using phenytoin and manipulation of mTOR pathway as examples.[30](#acn3364-bib-0030){ref-type="ref"}, [31](#acn3364-bib-0031){ref-type="ref"} We now show the utility of this in vitro model of chronic epilepsy as a first, blinded, moderate throughput stage for drug screening. Repeat biochemical as well as electrophysiological confirmation in vitro comprised the second stage of screening. The final stage was comprised of double blind, crossover controlled, in vivo testing in the kainate model of severe chronic epilepsy[9](#acn3364-bib-0009){ref-type="ref"}, [32](#acn3364-bib-0032){ref-type="ref"} with seizure quantification by continuous electrographic monitoring.[33](#acn3364-bib-0033){ref-type="ref"}

Materials and Methods {#acn3364-sec-0006}
=====================

Organotypic hippocampal cultures {#acn3364-sec-0007}
--------------------------------

Hippocampal slices of 350 *μ*m thickness were dissected from postnatal day 7--8 Sprague‐--Dawley male rat pups (Fig. [1](#acn3364-fig-0001){ref-type="fig"}A). Slices were placed onto poly‐D‐lysine (PDL)‐coated 6‐well tissue culture plates (Fig. [1](#acn3364-fig-0001){ref-type="fig"}B and C). Culture medium consisted of Neurobasal‐A/B27 supplemented with 0.5 mmol/L GlutaMAX and 30 *μ*g/mL gentamicin (Life Technologies). Slices were maintained at 37°C in a humidified atmosphere that contained 5% CO~2~. After attachment, culture plates were placed on a rocking platform (Fig. [1](#acn3364-fig-0001){ref-type="fig"}D and E). All of the procedures conformed to the NIH guidelines (i.e., as described in The Guide for Care and Use of Laboratory Animals) and were approved by the Massachusetts General Hospital Subcommittee on Research Animal Care.

![Screen design. (A) Twelve hippocampal slices derived from the same rat pup, imaged on day in vitro (DIV) 0 immediately after dissection. (B) Photograph of slice cultures in a poly‐D‐lysine‐coated 6‐well tissue culture plate with culture medium. (C) Twelve slices were cultured in four sets of triplicates, allowing for screening of four conditions per experiment. One of the four conditions tested per experiment was always a control (vehicle). (D) A single well of a 6‐well plate with a slice culture is shown in cross‐section on a rocking platform. Slice was offset from the center of the well allowing it to be submerged in culture medium and aerated in a continuously alternating manner during rocking. (E) Slices were cultured in 6‐well plates on a rocking platform in a humidified chamber with 5% CO ~2~ at 37°C. (F) Morphological progression of a control organotypic hippocampal slice culture over 24 days in vitro is shown in column 1. The toxic effects of various compounds (first application on DIV 3) on organotypic hippocampal slice cultures (columns 3--10) in comparison with a compound with a nontoxic effect (column 2) are also shown. (G) Lactate production and (H) Lactate dehydrogenase (LDH) release measured in spent culture media from control organotypic hippocampal slice cultures (*n* = 318 slices) as biomarkers of seizure‐like activity and ictal neuronal death, respectively. The lighter gray areas represent the overall population variation, whereas the darker gray areas represent the intertriplicate variation. Data are expressed as mean ± SD. (I) Chronic application experiments were carried out for 28 days in vitro with compounds added to culture media starting on DIV 3. Every 3--4 days, spent culture medium was collected and fresh culture medium with appropriate drug(s) was added to slice cultures. Collected spent culture medium was assayed for biomarkers of seizure activity and ictal neuronal death.](ACN3-3-908-g001){#acn3364-fig-0001}

Compound application and assays {#acn3364-sec-0008}
-------------------------------

We organized cultures into four experimental groups of three slices each, all from the same animal (Fig. [1](#acn3364-fig-0001){ref-type="fig"}C).

Compounds were applied starting from day in vitro (DIV) 3, and reapplied with every biweekly medium change (Fig. [1](#acn3364-fig-0001){ref-type="fig"}I), except wash‐out experiments where compound application stopped on indicated DIV. To blind the experimenter, compounds and vehicle controls were labeled with randomly assigned numbers. Maps of compound/vehicle numbers and corresponding experiments were maintained by a different investigator. Culture supernatant (spent culture medium) was collected and relative concentrations of markers of seizure‐like activity and ictal neuronal death, lactate, and LDH, were measured using commercially available kits (Biovision, Milpitas, CA).

Morphology scoring {#acn3364-sec-0009}
------------------

The natural progression of slice morphology over first 24 days in vitro is shown in the first column of Figure [1](#acn3364-fig-0001){ref-type="fig"}F. We noticed that some drugs significantly altered slice morphology, and that these changes correlated with the number of surviving neurons in the slice. We therefore developed a scoring metric for morphology that was used together with LDH measurements to screen drugs and compounds for toxicity. Slices that appeared lighter or same as controls were assigned a score of **0**, slices that were smaller or darker than controls were assigned a score of **1**, slices with significantly changed shape or with neuronal layers that were no longer distinguishable were assigned a score of **2**, and slices which disintegrated or detached from substrate were assigned a score of **3** (Fig. [1](#acn3364-fig-0001){ref-type="fig"}F).

Toxicity screening {#acn3364-sec-0010}
------------------

We found that some drugs were toxic to organotypic hippocampal cultures at applied concentrations, as measured by increased LDH on DIV 6/7 or by morphology scoring. While morphology and LDH were well correlated (*r* ^2^ = 0.6, *P* \< 0.001, *n* = 407 drug‐concentration pairs), several compounds or drugs increased LDH without a corresponding change in morphology, while others changed the morphology without a corresponding change in LDH (Fig. [2](#acn3364-fig-0002){ref-type="fig"}A). This may be due to different modes of cell death.[27](#acn3364-bib-0027){ref-type="ref"} We therefore adopted the following criteria for establishing toxicity of a given drug‐concentration pair: (1) morphology score \>0, or (2) LDH on DIV 6/7 that was significantly higher than control. If either criterion was satisfied by a drug‐concentration pair, this pair was deemed toxic and excluded from further analysis.

![Drug effects. (A) Lactate dehydrogenase (LDH) values and morphology scores on day in vitro (DIV) 6/7 were well correlated (R^2^ = 0.6019, *P* \< 0.001), suggesting that cell death led both to increased LDH release and changed culture morphology. However, in a few cases, applied compounds caused a significantly higher LDH release without accompanying change in morphology (brown outline). In other cases, differences in morphology were observed without a significant difference in LDH release (red outline). These compounds were also excluded from analysis. Compounds that were included in analysis are outlined in green. (B, C) Histograms of frequency of screened nontoxic compounds as fraction of controls for lactate production (B) and LDH release (C) (328 drug‐concentration pairs; *n* = 3 slices per pair). (D) Integrated lactate production (DIV 10--17), normalized to controls from the same pup versus integrated LDH production (DIV 1017), normalized to controls. *σ* = standard deviation of integrated lactate (horizontal axis) and LDH (vertical axis) of vehicle‐treated controls. Data are plotted for 328 drug‐concentration pairs. Effects of tetrodotoxin (D) and phenelzine (E) are highlighted for separate experiments (*n* = 3 each experiment) that were performed over 2--3 years to demonstrate reproducibility of the screen. (F) Histogram of effects of standard AEDs on seizure‐like activity (measured by lactate production) in organotypic hippocampal cultures. Normal distribution is included in the same plot for comparison. (G) Strictly standardized mean difference (SSMD) values of lactate and LDH production of drug‐treated cultures versus vehicle‐treated controls, evaluated between DIV 10--17. Significant results (SSMD \< −1.645 for both lactate and LDH) are highlighted with brown color. (H) Same plot as (G), shown in more detail.](ACN3-3-908-g002){#acn3364-fig-0002}

Data analysis and statistics {#acn3364-sec-0011}
----------------------------

The strictly standardized mean difference (SSMD) metric was used to identify hits in the compound screen. SSMD was calculated according to the following formula:

$\text{SSMD}_{i} = \frac{{\overline{X}}_{i} - {\overline{X}}_{N}}{\sqrt{{si}^{2} + {sN}^{2}}}$, where ${\overline{X}}_{i}$ is the mean of integrated lactate or LDH values for drug *i*, ${\overline{X}}_{N}$ is the mean of integrated lactate or LDH for matched control, and $S_{i}^{2}$ and $S_{N}^{2}$ are drug and control variances, respectively. SSMD captures information about both the size of the effect (difference between drug and control means) and significance of the result, similar to Cohen\'s D.[34](#acn3364-bib-0034){ref-type="ref"} We used the following criteria: \|SSMD\| \> 3 (very strong effect), 3 \> \|SSMD\| \> 2 (strong effect), 2 \> \|SSMD\| \> 1.645 (fairly strong effect), 1.645 \> \|SSMD\| \> 1 (moderate effect), 1 \> \|SSMD\| \> 0 (weak effect).[35](#acn3364-bib-0035){ref-type="ref"} *P* values for screen hits were calculated using Student\'s t‐test.

Acute recordings {#acn3364-sec-0012}
----------------

Extracellular field potentials were recorded in the CA1 and/or CA3 pyramidal cell layer of intact hippocampi[36](#acn3364-bib-0036){ref-type="ref"} and organotypic hippocampal slices in a conventional submerged chamber using tungsten‐coated microelectrodes and ISO‐DAM8A amplifier (World Precision Instruments). Oxygenated (95% O~2~ and 5% CO~2~) artificial cerebrospinal fluid containing 126 mmol/L NaCl, 3.5 mmol/L KCl, 2 mmol/L CaCl~2~, 1.3 mmol/L MgCl~2~, 25 mmol/L NaHCO~3~, 1.2 mmol/L NaH~2~PO~4~, and 11 mmol/L glucose (pH 7.4), was continuously perfused at 33 ± 0.5°C. Flow rate was 2.5 mL/min. Before the actual recording, slices were allowed to stabilize in the recording chamber for 30--60 min. Electrical signals were digitized using an analog‐to‐digital converter (DigiData 1322A, Axon Instruments). pCLAMP 8.2 (Axon Instruments) and SigmaPlot 11.0 (Systat Software) programs were used for data acquisition and analysis. Recordings were sampled at 10 KHz and filtered from 1 Hz to 2 kHz. Ictal‐like epileptiform discharges were defined as hyper‐synchronous large amplitude (×3 baseline) and high‐frequency population spikes followed by sustained ictal‐tonic and intermittent ictal‐clonic after discharges, with the duration of the population spike and after‐discharge complex lasting more than 5--10 sec. Power spectrum analysis was performed from the electrical signals after applying a Hamming window function.

In vivo experiments {#acn3364-sec-0013}
-------------------

### Kainate treatment and induction of status epilepticus {#acn3364-sec-0014}

A description of the methods for and characteristics of the repeated, low‐dose kainate model have been published in detail elsewhere.[9](#acn3364-bib-0009){ref-type="ref"}, [10](#acn3364-bib-0010){ref-type="ref"}, [37](#acn3364-bib-0037){ref-type="ref"} Briefly, convulsive status epilepticus was induced in adult male Sprague--Dawley rats (180--200 g) with repeated (i.e., approximately every 30 min), low‐dose (7.5 mg/kg), intraperitoneal (IP) injections of kainic acid (Tocris Bioscience, Bristol, UK). During and after the kainate treatment, all rats were maintained in a climate‐controlled vivarium. All of the procedures conformed to the NIH guidelines (i.e., as described in The Guide for Care and Use of Laboratory Animals) and were approved by the University of Utah Animal Care and Use Committee (IACUC).

### Surgical implantation of recording electrodes {#acn3364-sec-0015}

Rats with kainate‐induced epilepsy were implanted with cortical electroencephalogram (EEG) electrodes. The head was held in a stereotaxic device, and the surgical site was clipped and washed with Betadine scrub and solution. The rat was anesthetized with 2% isoflurane and pretreated with 0.8 mL subcutaneous atropine (0.54 mg/kg) and 0.2 mL subcutaneous dexamethasone (4 mg/mL). After the incision and retraction of the skin, the dura was removed and six small holes were drilled through the skull, for implantation of support screws and electrodes. A bipolar stainless‐steel recording electrode pedestal was lowered onto the cortex of the right hemisphere (4.0 mm lateral, 8.0 mm caudal), and a ground electrode was placed on the cortex of the left hemisphere (2.0 mm lateral, 3.5 mm rostral). Dental acrylic fastened the electrode pedestal into place and covered and sealed the exposed skull surfaces. The incision was closed with 4--0 Dermalon sutures to the level of the dental cement covering the skull. Animals were then administered subcutaneous treatments of 3.0 mL lactated Ringer\'s, 0.1 mL marcaine (0.5%), 0.1 mL buprenorphine (0.3 mg/mL), and 0.2 mL penicillin (300,000 IU).

### Chronic in vivo recordings {#acn3364-sec-0016}

Rats with kainate‐induced epilepsy and implanted electrodes were placed in custom‐built Plexiglass recording chambers equipped with swivel commutators, and connected to spring‐covered cables (Plastics One, Roanoke, VA) to their skull caps. Electrographic signals were amplified with EEG100C amplifiers (high‐pass at 1 Hz; low‐pass at 100 Hz; notch filter at 60 Hz), digitized at 500 Hz with an MP150 digital‐analog converter, and acquired with AcqKnowledge software (BioPac Systems Inc.; Santa Barbara, California). Electrographic recordings were obtained continuously during vehicle and drug treatments. Data were stored on hard‐drives for offline analysis using AcqKnowledge software.

### Repeated‐measures, crossover protocol for drug testing {#acn3364-sec-0017}

Long‐term, continuous recording sessions were used to assess the effect of Celecoxib‐containing food versus control food on spontaneous recurrent electrographic seizures. A repeated‐measure, crossover protocol was used with 100 mg/kg/day Celecoxib in custom‐made food (Bio‐serv).[38](#acn3364-bib-0038){ref-type="ref"} The 100 mg/kg/day dose of Celecoxib would be equivalent to five injections of 20 mg/kg/day.[39](#acn3364-bib-0039){ref-type="ref"} Each trial involved eight treatments of Celecoxib and eight vehicle treatments administered on alternate days with two recovery days between the treatment days. The rationale for the repeated‐measure, crossover design was the high degree of statistical power inherent in this approach. For example, for *α* = 0.05, eight animals and six drug‐versus‐vehicle crossovers (i.e., a total of 48 drug‐versus‐vehicle tests per trial[38](#acn3364-bib-0038){ref-type="ref"}) yields a power of 0.9.

### Blinded seizure detection {#acn3364-sec-0018}

EEG acquisition and analysis were performed at separate sites by different investigators. DClamp (sourceforge.net) was used to detect seizures using supervised algorithms.[33](#acn3364-bib-0033){ref-type="ref"} Detection parameters were set to increase sensitivity to the point that seizures were rarely missed in trial detections, but false‐positive detections were common. Human supervision consisted of review of all detected seizures for false‐positive detections and review of raw EEG for false negatives. In total, 532 true positives, 18578 false positives, and 94 false negatives were found. To blind the supervising investigator, the EEG files and channels were renamed using random numbers, and the map to the original names was managed by an investigator not involved in the analysis.

Results {#acn3364-sec-0019}
=======

Lactate and LDH in control cultures {#acn3364-sec-0020}
-----------------------------------

We followed the natural progression of lactate and LDH production by epileptic control cultures from DIV 6 to DIV 28 (Fig. [1](#acn3364-fig-0001){ref-type="fig"}, *n* = 318). Lactate and LDH production reached their peaks between DIV 14 and 17 (Fig. [1](#acn3364-fig-0001){ref-type="fig"}G and H). Decrease in lactate and LDH production at later time points is likely a consequence of seizure‐induced neuron death, the peak of which occurs between DIV 14 and 17.[30](#acn3364-bib-0030){ref-type="ref"} We therefore used the period between DIV 10 and DIV 17 (the time between the onset of spontaneous seizure‐like activity and significant neuron death) to compare lactate and LDH production in vehicle‐treated and drug‐treated cultures. We found that variability between cultures dissected from the same animal was lower than variability between cultures dissected from different animals (Fig. [1](#acn3364-fig-0001){ref-type="fig"}G and H). To control for interanimal differences, all experimental assays were compared to vehicle‐treated cultures from the same animal.

Compound screen results {#acn3364-sec-0021}
-----------------------

We screened 140 compounds, including combinations of drugs (Table [1](#acn3364-tbl-0001){ref-type="table-wrap"}). Different concentrations were used for each drug, and a total of 407 drug‐concentration pairs were screened in triplicate (*n* = 3 slices). Of these, 79 were found to be toxic (Table [2](#acn3364-tbl-0002){ref-type="table-wrap"}) and excluded from further analysis (Fig. [2](#acn3364-fig-0002){ref-type="fig"}A). We integrated the lactate and LDH production of the remaining 328 drug‐concentration pairs between DIV 10 and DIV 17 (*n* = 3), and normalized it by control (vehicle‐treated cultures from the same pup, *n* = 3) lactate and LDH production over the same period. Histograms of lactate and LDH production are shown in Figure [2](#acn3364-fig-0002){ref-type="fig"}B and C, and a scatter plot of lactate versus LDH is shown in Figure [2](#acn3364-fig-0002){ref-type="fig"}D. Values that are lower than unity indicate that a drug lowered lactate and/or LDH production to a level below that of a vehicle‐treated control. Some of the low lactate and LDH values were less than the mean standard deviation lower than the mean of controls, suggesting that significant reduction of seizure‐like.

###### 

List of screened drugs and compounds

  ----------------------------- --------------------- ----------------------- ------------------- --------------------- -----------------------
  **Anticonvulsants**           **Cholinergic**       **Glutamate**           **Dopamine**        **Chloride**          **Antiinflammatory**
  Carbamazepine                 Amantadine HCl        ACPD                    Clomipramine        Acetazolamide         Carprofen
  Diazepam                      Atropine sulfate      CPPG                    Dopamine HCl        Bumetanide            Celecoxib
  Ethosuximide                  Carbachol             DCG IV                  Haloperidol         Chlorothiazide        Celecoxib +
  Felbamate                     Diphenhydramine       Dextromethorphan                            CLP257\*              Phenytoin
  Gabapentin                    Edrophonium           HBr                     **Serotonin**       D4.2\*                Deracoxib
  Levetiracetam (keppra)        Nicotine bitartrate   dL APV                  Ketanserin          Furosemide            Diclofenac
  Phenacemide                                         Kynurenic acid          Tartrate            IS50699\*             Firocoxib
  Phenobarbital                 **Monoamine NT**      L‐AP4                   Methysergide        Mannitol              Indomethacin
  Phenobarbital +               **modulators**        LY341495                Zolmitriptan                              Ketoprofen
  Bumetanide                    Amitriptyline         MPEP                                        **Sodium**            Ketorolac
  Phenytoin                     Amoxapine                                     **Opioid**          Bretylium Tosylate    LOXBlock‐1\*
  Pregabalin                    Atomoxetine           **GABA**                Nalbuphine HCl      Digoxin               Meclofenamate
  Retigabine                    Bupropion             Baclofen                Naloxone            Lidocaine HCl         Meloxicam
  Topiramate                    Clonidine             CGP55845                Tramadol            Tetrodotoxin (TTX)    Piroxicam
  Valproic acid                 Desipramine           Diazepam + CLP257       TG4‐155\*           TTX + Fluoxetine      Rofecoxib
                                Doxepin               Diazepam + IS50699                          TTX + Nortriptyline   Sulindac
  **Intracellular signaling**   Duloxetine            Flurothyl               **Cannabinoid**                           Zileuton
  AG 1024                       Fluoxetine            Gabazine                Rimonobant          **Calcium**           
  Akt 1,2 kinase inhibitor      Imipramine            Taurine                                     Flunarizine           **Antioxidant**
  API‐2 (Triciribine)           Maprotiline                                   **Purine**          Verapamil             Acetylcysteine
  DFMO                          Methylphenidate HCl   **Microtubule**         Allopurinol                               Alpha‐tocopherol
  Gefitinib (Iressa)            Modafinil             Colchicine              Caffeine            **Potassium**         GCEE\*
  K‐252a                        Nortriptyline         Vinblastine                                 Glipizide             
  Lyothyronine                  Phenelzine            Vincristine             **Steroids**                              **Growth factor**
  PDMP\*                        Phenelzine + TTX                              Dexamethasone       **Blinded**           Neuregulin‐1\*
  Picropodophyllotoxin          Propranolol           **Antiproliferative**   Estradiol           LacCer\*              
  Rapamycin                     Reserpine             Carboplatin             Letrozole           LDN‐209884(3‐1)\*     **Cell death**
  Sildenafil Citrate            Selegiline            Cycloheximide           Lovastatin          LDN‐212320(10‐10)\*   Caspase‐3 inhibitor\*
  TGFbeta RI inhibitor\*        Sertraline            Etoposide               Megestrol           LDN‐72457(5‐1)\*      Erythropoietin
  TrkB Fc chimera               Venlafaxine           AG 1478                 Tamoxifen citrate                         Minocycline
  ----------------------------- --------------------- ----------------------- ------------------- --------------------- -----------------------

Drugs marked with an asterisk were obtained from collaborators, while the rest of the drugs were primarily obtained from the NINDS custom compound collection of known bioactives and FDA‐approved drugs.

John Wiley & Sons, Ltd

###### 

List of drug‐concentration pairs excluded from analysis due to early toxicity

  Drug name                  Concentration   Drug name              Concentration              Drug name              Concentration
  -------------------------- --------------- ---------------------- -------------------------- ---------------------- ---------------------------
  Akt 1/2 kinase inhibitor   10 *μ*mol/L     Dextromethorphan HBr   10 *μ*mol/L                Maprotiline            10 *μ*mol/L
  Akt 1/2 kinase inhibitor   5 *μ*mol/L      DFMO                   40 *μ*mol/L                Megestrol acetate      10 *μ*mol/L
  Akt 1/2 kinase inhibitor   2 *μ*mol/L      Diazepam + IS50699     1 + 10 *μ*mol/L            Minocycline            500 *μ*mol/L
  Alpha‐tocopherol           10 *μ*mol/L     Duloxetine             10 *μ*mol/L                Minocycline            100 *μ*mol/L
  Alpha‐tocopherol           1 *μ*mol/L      Erythropoietin         100 IU/mL                  Nortriptyline          10 *μ*mol/L
  Alpha‐tocopherol           0.1 *μ*mol/L    Erythropoietin         10 IU/mL                   Nortriptyline + TTX    10 *μ*mol/L + 1 *μ*mol/L
  Amitriptyline              10 *μ*mol/L     Erythropoietin         1 IU/mL                    Nortriptyline + TTX    1 *μ*mol/L + 1 *μ*mol/L
  Amoxapine                  10 *μ*mol/L     Felbamate              1 *μ*mol/L                 PDMP                   50 *μ*mol/L
  API‐2 (Triciribine)        10 *μ*mol/L     Flunarizine            10 *μ*mol/L                PDMP                   25 *μ*mol/L
  API‐2 (Triciribine)        5 *μ*mol/L      Fluoxetine             10 *μ*mol/L                Phenelzine + TTX       1 *μ*mol/L + 1 *μ*mol/L
  API‐2 (Triciribine)        2 *μ*mol/L      Fluoxetine             2 *μ*mol/L                 Phenelzine + TTX       0.1 *μ*mol/L + 1 *μ*mol/L
  API‐2 (Triciribine)        1 *μ*mol/L      Fluoxetine + TTX       10 *μ*mol/L + 1 *μ*mol/L   Picropodophyllotoxin   10 *μ*mol/L
  Bupropion                  10 *μ*mol/L     Gefitinib (Iressa)     10 *μ*mol/L                Picropodophyllotoxin   5 *μ*mol/L
  Caspase‐3 inhibitor        10 *μ*mol/L     Gefitinib (Iressa)     1 *μ*mol/L                 Picropodophyllotoxin   2 *μ*mol/L
  CGP55845                   1 *μ*mol/L      Gefitinib (Iressa)     0.1 *μ*mol/L               Picropodophyllotoxin   1 *μ*mol/L
  CGP55845                   0.1 *μ*mol/L    IS50699                10 *μ*mol/L                Piroxicam              10 *μ*mol/L
  CGP55845                   0.01 *μ*mol/L   IS50699                10 *μ*mol/L                Rimonabant             10 *μ*mol/L
  Clomipramine               10 *μ*mol/L     K‐252a                 1 *μ*mol/L                 Sertraline             10 *μ*mol/L
  CLP257                     100 *μ*mol/L    K‐252a                 0.3 *μ*mol/L               Sertraline             2 *μ*mol/L
  CLP257                     100 *μ*mol/L    Ketanserin tartrate    1 *μ*mol/L                 Tamoxifen citrate      10 *μ*mol/L
  Colchicine                 1 *μ*mol/L      Ketanserin tartrate    0.1 *μ*mol/L               TrkB Fc chimera        1 *μ*g/mL
  Colchicine                 0.1 *μ*mol/L    Ketanserin tartrate    0.01 *μ*mol/L              Verapamil              100 *μ*mol/L
  Colchicine                 0.1 *μ*mol/L    LacCer                 20 *μ*g/mL                 Verapamil              10 *μ*mol/L
  D4.2                       10 *μ*mol/L     LacCer                 10 *μ*g/mL                 Vinblastine            0.1 *μ*mol/L
  DCG IV                     10 *μ*mol/L     LDN‐212320(10‐10)      10 *μ*mol/L                Vincristine            0.1 *μ*mol/L
  DCG IV                     1 *μ*mol/L      Lidocaine HCl          10 *μ*mol/L                                       
  Desipramine                10 *μ*mol/L     Lovastatin             10 *μ*mol/L                                       

John Wiley & Sons, Ltd

We examined the long‐term reproducibility of our drug screening methodology by comparing values obtained over a period of 2--3 years (Fig. [2](#acn3364-fig-0002){ref-type="fig"}D and E). Lactate and LDH values for tetrodotoxin and phenelzine were found to reliably cluster into the same regions of lactate versus LDH scatter plot, demonstrating the stability and reproducibility of our results.

Our screen included 42 drug‐concentration pairs (*n* = 3 per drug‐concentration pair) of standard antiepileptic drugs (AEDs), including acetazolamide (10 *μ*mol/L), carbamazepine (10--70 *μ*mol/L), diazepam (1 *μ*mol/L), ethosuximide (10--1000 *μ*mol/L), felbamate (0.01--1 *μ*mol/L), gabapentin (1--50 *μ*mol/L), levetiracetam (10--250 *μ*mol/L), phenacemide (0.01--1 *μ*mol/L), phenobarbital (100 *μ*m), phenytoin (100 *μ*mol/L), pregabalin (0.01--1 *μ*mol/L), topiramate (10--100 *μ*mol/L), and valproate (600 *μ*mol/L). A histogram of the effects of these drugs on lactate production, a marker of seizure‐like activity in organotypics, is shown in Figure [2](#acn3364-fig-0002){ref-type="fig"}F. Data for individual drug‐concentration pairs are included in Table S1. Phenytoin was most effective, but seizure activity recrudesces after 3 weeks of exposure, that is, the slice cultures become refractory to phenytoin.[30](#acn3364-bib-0030){ref-type="ref"}

We used the strictly standardized mean difference (SSMD) metric to make a robust determination of the significance of screen results, and to identify "hits". SSMD takes both effect size and data variance into account, thus identifying hits that have the strongest and most statistically significant effect. We used a cutoff of SSMD \<−1.645 to identify hits with a fairly strong[35](#acn3364-bib-0035){ref-type="ref"} reduction of both lactate and LDH production (Fig. [2](#acn3364-fig-0002){ref-type="fig"}G, H, and Table [3](#acn3364-tbl-0003){ref-type="table-wrap"}). Results for all screened compounds are listed in the Table S1.

###### 

Hits discovered with the screen (hits are highlighted in Figs [2](#acn3364-fig-0002){ref-type="fig"}F, G)

  Drug name                    Concentration       Integrated, normalized lactate production   Integrated, normalized LDH production   *p* ~lactate~   *p* ~LDH~   SSMD~lactate~   SSMD~LDH~
  ---------------------------- ------------------- ------------------------------------------- --------------------------------------- --------------- ----------- --------------- -----------
  Celecoxib + Phenytoin        10 + 100 *μ*mol/L   0.41                                        0.49                                    2.133E‐07       3.355E‐05   −42.04          −11.83
  Celecoxib + Phenytoin        10 + 100 *μ*mol/L   0.43                                        0.64                                    7.663E‐07       2.267E‐04   −30.52          −7.29
  Celecoxib                    10 *μ*mol/L         0.59                                        0.70                                    0.0001          0.0006      −9.60           −5.57
  Celecoxib + Phenytoin        10 + 100 *μ*mol/L   0.30                                        0.39                                    0.0001          1.374E‐05   −9.51           −14.81
  Celecoxib                    10 *μ*mol/L         0.72                                        0.75                                    0.0001          0.0006      −8.25           −5.60
  API‐2 (Triciribine)          0.5 *μ*mol/L        0.40                                        0.30                                    0.0002          0.0007      −7.47           −5.45
  Cycloheximide                1 *μ*mol/L          0.54                                        0.34                                    0.0003          1.879E‐08   −6.85           −77.17
  TTX                          1 *μ*mol/L          0.53                                        0.61                                    0.0004          0.0008      −6.17           −5.27
  Taurine                      100 *μ*mol/L        0.73                                        0.32                                    0.0005          3.627E‐05   −5.97           −11.60
  Celecoxib                    10 *μ*mol/L         0.69                                        0.58                                    0.0006          0.0008      −5.62           −5.34
  LDN‐212320 (10‐10)           3 *μ*mol/L          0.57                                        0.76                                    0.0007          0.0002      −5.54           −7.55
  Akt 1/2 kinase inhibitor     1 *μ*mol/L          0.75                                        0.54                                    0.0007          0.0055      −5.42           −3.15
  Akt 1/2 kinase inhibitor     0.5 *μ*mol/L        0.85                                        0.59                                    0.0008          0.0002      −5.33           −7.39
  Phenytoin                    100 *μ*mol/L        0.48                                        0.57                                    4.460E‐05       0.0001      −5.23           −4.34
  Doxepin                      10 *μ*mol/L         0.62                                        0.80                                    0.0011          0.0050      −4.90           −3.22
  Rapamycin (DIV3--28)         20 nmol/L           0.59                                        0.14                                    0.0011          0.0034      −4.84           −3.60
  TTX                          1 *μ*mol/L          0.48                                        0.60                                    0.0013          0.0060      −4.66           −3.07
  Celecoxib                    10 *μ*mol/L         0.58                                        0.59                                    0.0014          0.0001      −4.56           −9.66
  API‐2 (Triciribine)          0.2 *μ*mol/L        0.70                                        0.49                                    0.0031          0.0024      −3.70           −3.96
  Topiramate                   100 *μ*mol/L        0.82                                        0.79                                    0.0036          0.0423      −3.53           −1.70
  Kynurenic acid               3 mmol/L            0.51                                        0.65                                    0.0004          0.0050      −3.51           −2.16
  TTX + Fluoxetine             1 + 1 *μ*mol/L      0.63                                        0.55                                    0.0049          0.0004      −3.24           −6.32
  Phenobarbital + Bumetanide   100 + 10 *μ*mol/L   0.86                                        0.81                                    0.0052          0.0420      −3.20           −1.70
  TTX                          1 *μ*mol/L          0.58                                        0.76                                    0.0058          0.0114      −3.10           −2.56
  TTX                          1 *μ*mol/L          0.53                                        0.52                                    0.0059          0.0370      −3.09           −1.78
  Rapamycin (DIV 3--14)        20 nmol/L           0.67                                        0.41                                    0.0088          0.0010      −2.76           −4.92
  Vinblastine                  0.01 *μ*mol/L       0.66                                        0.55                                    0.0096          0.0031      −2.69           −3.70
  Neuregulin‐1                 10 ng/mL            0.80                                        0.76                                    0.0096          0.0010      −2.69           −5.02
  LDN‐72457 (5‐1)              10 *μ*mol/L         0.70                                        0.75                                    0.0103          0.0049      −2.64           −3.25
  Picropodophyllotoxin         0.5 *μ*mol/L        0.71                                        0.28                                    0.0110          0.0038      −2.59           −3.50
  Rapamycin (DIV3--14)         20 nmol/L           0.59                                        0.12                                    0.0135          0.0032      −2.44           −3.67
  Acetylcysteine               50 *μ*mol/L         0.85                                        0.64                                    0.0135          0.0038      −2.43           −3.49
  Furosemide                   1 mmol/L            0.71                                        0.53                                    0.0143          0.0038      −2.40           −3.49
  Neuregulin‐1                 100 ng/mL           0.81                                        0.76                                    0.0167          0.0013      −2.28           −4.61
  Phenytoin                    100 *μ*mol/L        0.46                                        0.50                                    0.0044          0.0033      −2.22           −2.35
  Celecoxib                    10 *μ*mol/L         0.67                                        0.57                                    0.0213          0.0023      −2.12           −3.98
  Colchicine                   0.01 *μ*mol/L       0.81                                        0.48                                    0.0268          0.0051      −1.97           −3.22
  Akt 1/2 kinase inhibitor     1 *μ*mol/L          0.79                                        0.29                                    0.0315          0.0001      −1.87           −9.43
  GCEE                         1 mmol/L            0.73                                        0.47                                    0.0325          2.938E‐05   −1.85           −12.23
  Neuregulin‐1                 1 ng/mL             0.88                                        0.83                                    0.0334          0.0018      −1.84           −4.29
  Rapamycin (DIV 3 \> )        20 nmol/L           0.76                                        0.46                                    0.0339          0.0028      −1.83           −3.80
  Diazepam + CLP257            1 + 100 *μ*mol/L    0.69                                        0.35                                    0.0386          0.0002      −1.75           −7.11
  Carbamazepine                50 *μ*mol/L         0.84                                        0.56                                    0.0415          0.0002      −1.71           −7.56
  Kynurenic acid               3 mmol/L            0.54                                        0.60                                    0.0151          0.0165      −1.68           −1.65

Compounds are organized based on increasing lactate SSMD. *P* values were calculated relative to vehicle‐treated controls from the same pup. Repeated drug‐concentration pairs represent replicated experiments in different animals.

John Wiley & Sons, Ltd

Celecoxib effect on lactate and LDH production {#acn3364-sec-0022}
----------------------------------------------

We found that celecoxib, an antiinflammatory drug applied at the concentration of 10 *μ*mol/L, was a strong inhibitor of lactate and LDH production in five separate experiments (*n* = 3 cultures, each experiment, −9.6 \< SSMD~lactate~ \<−2.1, −9.7 SSMD~LDH~ \<−4). Lower concentration, 1 *μ*mol/L, was less effective, while 100 *μ*mol/L celecoxib was toxic to organotypic cultures (Figure S1). In contrast, other antiinflammatory drugs that we have tested did not have as strong effect on lactate and LDH production (Fig. [3](#acn3364-fig-0003){ref-type="fig"}A).

![Anticonvulsive and neuroprotective effects of celecoxib, phenytoin, and celecoxib plus phenytoin. (A) The effects of celecoxib (*n* = 5 screens; three slices per screen) and 13 other screened antiinflammatory drugs (*n* = 18 screens; three slices per screen) in comparison with all screened nontoxic compounds. (B) The effects of celecoxib (10 *μ*mol/L; *n* = 5 screens), phenytoin (100 *μ*mol/L; *n* = 4 screens), and a combination of celecoxib (10 *μ*mol/L) plus phenytoin (100 *μ*mol/L) (*n* = 3 screens) in comparison with all screened nontoxic compounds. *n* = 3 slices per screen. (C, D) Lactate production (C) and lactate dehydrogenase (LDH) release (D), normalized to controls, for celecoxib (10 *μ*mol/L), phenytoin (100 *μ*mol/L), and celecoxib (10 *μ*mol/L) plus phenytoin (100 *μ*mol/L), two separate experiments with three slices per experiment per compound including control (*n* = 6), throughout a 4‐week chronic application phase followed by a 4‐day wash‐out phase.](ACN3-3-908-g003){#acn3364-fig-0003}

We have previously found that anticonvulsant phenytoin is effective at suppressing ictal‐like activity and seizure‐induced cell death in this model of epilepsy, although the effect was temporary.[30](#acn3364-bib-0030){ref-type="ref"} Since phenytoin and celecoxib are likely reducing seizures through different mechanisms, we examined whether celecoxib + phenytoin (C+P) combination would have a stronger and/or longer lasting effect on lactate and LDH production than celecoxib or phenytoin alone. We found that this was the case, with C+P combination reducing both lactate and LDH production beyond that of celecoxib or phenytoin alone by DIV 14 (Fig. [3](#acn3364-fig-0003){ref-type="fig"}C and D, lactate *P* \< 0.001 versus celecoxib or phenytoin alone, LDH *P* \< 0.001 versus phenytoin alone, and *P* = 0.019 versus celecoxib alone, values from ANOVA with Bonferroni post hoc analysis, *n* = 6 each condition). Phenytoin and celecoxib were no longer effective in reducing lactate release from cultures by DIV 21, but effectiveness of C+P combination persisted until DIV 27 (C+P vs. vehicle, lactate *P* \< 0.001). However, reduction in lactate release was no longer observed after wash‐out of all drugs on DIV 28. We examined the effects of drug wash‐out by comparing lactate values on DIV 27 (just before wash‐out) and DIV 30 (3 days after wash‐out). LDH values were compared between DIV 27 and DIV 31, since seizure‐induced cell death peak occurs slightly after the seizure peak in this model. We found that lactate and LDH release significantly increased in celecoxib‐treated cultures after celecoxib wash‐out (*P* \< 0.001 lactate, *P* = 0.024 LDH, paired t‐test), and in C+P‐treated cultures after C+P wash‐out (*P* \< 0.001 lactate, *P* = 0.007 LDH, paired t‐test), suggesting that celecoxib has a strong anticonvulsant, but not an antiepileptic, effect.

Lack of celecoxib effect in acute seizure model {#acn3364-sec-0023}
-----------------------------------------------

Recurrent seizures were induced in intact hippocampus preparation by perfusion of low‐Mg artificial cerebrospinal fluid (aCSF). The extracellular field potential was monitored in the CA3 area in a recording chamber perfused with low‐Mg aCSF (Fig. [4](#acn3364-fig-0004){ref-type="fig"}A). The first appearance of seizure‐like activity was observed 25.2 ± 5.0 min after exposure to low‐Mg aCSF. After initial 3--10 seizures, seizure‐like activities were recorded over 1 h as baseline and then 10 *μ*mol/L celecoxib was bath applied for another hour. Compared with baseline data before application, seizure parameters such as total number, percent change, and mean duration of seizures were not changed significantly by celecoxib (Fig. [4](#acn3364-fig-0004){ref-type="fig"}B) (*P* = 0.86, 0.8, and 0.25, respectively, *n* = 5). Interseizure interval tends to gradually decrease in this preparation over time,[36](#acn3364-bib-0036){ref-type="ref"} but celecoxib did not revert this trend (Fig. [4](#acn3364-fig-0004){ref-type="fig"}B). All these results indicate that celecoxib has no effect on acute epileptiform activity induced by low‐Mg in intact hippocampi from naïve animals.

![Celecoxib effects in vitro. (A) Application of celecoxib to intact hippocampal preparation in low‐Mg aCSF. A representative trace of field potential from intact hippocampal preparation treated with 10 *μ*mol/L celecoxib with induced seizure‐like activity is shown. (B) Quantification of frequency and mean duration of seizure‐like activity showed that application of celecoxib did not alter those parameters in the intact hippocampal preparation. Different symbols and shading represent results from individual hippocampi. (C) Representative traces of field potential from organotypic hippocampal cultures treated with 10 *μ*mol/L celecoxib or vehicle (DMSO). Inverted triangle indicates seizure‐like activity. (D, F) Frequency of seizure and power during bath application of celecoxib (black circle) or vehicle (gray circle) in younger slices (D) day in vitro (DIV 10--15; *n* = 8 slices per group) and older slices (F) (DIV 20--25; *n* = 8 for celecoxib and *n* = 6 for vehicle). (E, G) Comparison of frequency, total duration of seizure, and power, before and during exposure of celecoxib in younger slices (E) and older slices (G). (H, I) Hippocampal slices (*n* = 7) were cultured in the presence of 10 *μ*mol/L celecoxib for 4 weeks and then washed out by artificial CSF for 7 h. Representative recording demonstrates the reappearance of seizure‐like activity after wash‐out. Error bars represent SEM, \**P* \< 0.05 (t‐test). Statistical values were determined by one‐way analysis of variance or paired t‐test.](ACN3-3-908-g004){#acn3364-fig-0004}

Electrographic effects of celecoxib in chronic seizure models {#acn3364-sec-0024}
-------------------------------------------------------------

### Organotypic hippocampal cultures {#acn3364-sec-0025}

We monitored extracellular field potentials in areas CA1 and CA3 simultaneously in organotypic hippocampal slice cultures at two time points, early (DIV 10--15) and late (DIV 25--20). Extracellular field potentials were recorded with celecoxib, vehicle, or neither. The acute effect of celecoxib was observed 10--20 min after the start of continuous application (Fig. [4](#acn3364-fig-0004){ref-type="fig"}C). Celecoxib‐treated slices were compared to vehicle‐treated slices to control for any temporal variance in epileptiform activity. In early slice cultures, 10 *μ*mol/L celecoxib significantly reduced frequency of seizure‐like activity and the power of the field potential (*n* = 8, *P* = 0.01 and 0.047 for frequency and power reductions, respectively) (Fig. [4](#acn3364-fig-0004){ref-type="fig"}D). Celecoxib (10 *μ*mol/L) also reduced seizure frequency, total duration of seizures, and total power when compared to baseline activity (prior to celecoxib in the same preparation; *n* = 8, *P* = 0.17, 0.02. 0.001, respectively). These data indicate that celecoxib exerts an acute anticonvulsant effect in chronically epileptic brain tissue in vitro (Fig. [4](#acn3364-fig-0004){ref-type="fig"}E), and that the inhibition of lactate production by celecoxib (Fig. [3](#acn3364-fig-0003){ref-type="fig"}) is due to an effect of celecoxib on seizures.

We also tested celecoxib effects on epileptiform activity recorded extracellularly in older slices with more advanced epilepsy[30](#acn3364-bib-0030){ref-type="ref"}, [40](#acn3364-bib-0040){ref-type="ref"} at 25--30 days of culture (Fig. [4](#acn3364-fig-0004){ref-type="fig"}F and G). Differences in seizure frequency and power between celecoxib and vehicle‐treated groups were significant (*n* = 6--8, *P* = 0.003 and 0.01, respectively). Frequency and total duration of seizure‐like activity decreased with celecoxib treatment (*P* = 0.08 and 0.01, respectively). This indicates an age‐independent effect of celecoxib treatment.

Next, we tested the effects of long‐term application of celecoxib followed by wash‐out to differentiate antiepileptogenic versus reversible anticonvulsant effects of celecoxib. Slices were incubated with 10 *μ*mol/L celecoxib for 4 weeks and were then transferred to the recording chamber. Extracellular field potentials were recorded while applying 10 *μ*mol/L celecoxib for 2 h to establish the baseline, and then aCSF only for 7 h to wash celecoxib out (Fig. [4](#acn3364-fig-0004){ref-type="fig"}H). Seizure‐like activity was not observed in most of slices during celecoxib application but reappeared after wash‐out (Fig. [4](#acn3364-fig-0004){ref-type="fig"}I) (*n* = 7, *P* = 0.05, comparison of seizure frequency in celecoxib and after wash‐out). This observation suggests that celecoxib functions as an anticonvulsant rather than an antiepileptogenic drug in organotypic hippocampal culture model of epilepsy.

### Rats with kainate‐induced epilepsy {#acn3364-sec-0026}

Rats were continuously monitored with traditional wired EEG beginning 2 months after epileptogenic kainate administration Rats were treated with either drug‐containing food or food without the drug on day 1 and then observed through day 3.[32](#acn3364-bib-0032){ref-type="ref"}, [38](#acn3364-bib-0038){ref-type="ref"} On day 4, the rats were crossed over to the other treatment (i.e., placebo if the first treatment was celecoxib), and observed through day 6. Continuous electrographic recordings through the entire 6‐day cycle were analyzed for seizures (Fig. [5](#acn3364-fig-0005){ref-type="fig"}B).

![Celecoxib effects in vivo. (A) Raw electroencephalogram (EEG) recording of a seizure (top). First derivative of EEG recording (bottom); spikes marked automatically by dClamp illustrated with red dots. (B) Raster plot of seizure activity in rats (*n* = 8). Celecoxib treatment illustrated in pink; placebo treatment illustrated in yellow; rats removed from experiment illustrated with dashed line. (C) Average number of seizures per rat per day decreases following celecoxib treatment and increases following placebo treatment; data expressed as mean ± SEM (paired samples t‐test, \**P* = 0.0116). (D) Ratio of average number of seizures per rat per day showing effect of celecoxib treatment compared to placebo treatment. (E) Randomization of the order of interseizure intervals for each rat over total time course of experiment demonstrated two cases of false significance (*P* ≤ 0.0116, marked in red) for 1000 iterations.](ACN3-3-908-g005){#acn3364-fig-0005}

Celecoxib treatment caused a significant reduction in seizure frequency compared to placebo (Fig. [5](#acn3364-fig-0005){ref-type="fig"}C and D; *P* = 0.0116, paired t‐test). Of note, seizures were clustered in this crossover study (Fig. [5](#acn3364-fig-0005){ref-type="fig"}B), so that the seizure intervals did not follow a random (Poisson) distribution. To exclude the possibility of a spuriously significant effect of celecoxib due to clustering, we randomly assigned the same clustered distribution of seizure intervals to test how often a significant result could be obtained by chance. Consistent with the paired samples t‐test, we found that only two randomizations out of 1000 produced a significant difference with *P* ≤ 0.0116 by chance (Fig. [5](#acn3364-fig-0005){ref-type="fig"}E). Thus, the in vivo testing in the kainate model of chronic epilepsy supported the findings of the biochemical and electrophysiological in vitro screening.

Discussion {#acn3364-sec-0027}
==========

Existing anticonvulsant drugs are ineffective in approximately 30% of patients. This may be due to an anticonvulsant drug discovery pipeline that relies on chemically or electrically induced seizures in otherwise normal brain tissue.[4](#acn3364-bib-0004){ref-type="ref"}, [6](#acn3364-bib-0006){ref-type="ref"} However, chronically epileptic tissue is significantly different from normal tissue,[41](#acn3364-bib-0041){ref-type="ref"} and may respond differently to drugs. We developed a three‐stage pipeline for discovering new anticonvulsants that relies on chronic epilepsy models at each stage. The organotypic hippocampal culture in vitro model of epilepsy was used in the first stage along with biomarkers of seizures to achieve the highest experimental throughput. Electrographic screening in organotypic hippocampal cultures was then used in the second stage to verify biomarker results. Upon electrographic confirmation in vitro, in vivo experiments were conducted in the kainate model of chronic epilepsy with continuous electrographic monitoring.

The use of organotypic hippocampal cultures, where epileptogenesis occurs on a compressed time scale,[23](#acn3364-bib-0023){ref-type="ref"}, [24](#acn3364-bib-0024){ref-type="ref"} and where seizures and seizure‐induced cell death can be easily quantified with biomarker assays,[30](#acn3364-bib-0030){ref-type="ref"}, [31](#acn3364-bib-0031){ref-type="ref"} allowed us to circumvent the throughput limitations of in vivo chronic epilepsy models.[4](#acn3364-bib-0004){ref-type="ref"} Thus, we were able to screen 140 compounds and combinations of compounds, in over 400 separate drug‐concentration experiments, and identify over 40 hits.

We discovered that celecoxib, a selective COX2 inhibitor, was surprisingly effective at inhibiting biomarkers of seizures and seizure‐related cell death. We verified these results in a second stage of screening using electrographic seizure quantification in organotypic cultures, and in the final stage of screening in vivo in the kainate model. Interestingly, celecoxib was not effective in attenuating acutely induced seizures in the intact hippocampal preparation, demonstrating that an anticonvulsant discovery pipeline that relies on induced seizures in normal brain tissue would likely miss the anticonvulsant effects of this compound.

Several other compounds with similar COX2 inhibitory efficacy exhibited much more modest anticonvulsant effects in the organotypic model (Fig. [3](#acn3364-fig-0003){ref-type="fig"}A). Celecoxib also enhances the inhibitory potassium M current and reduces excitatory L‐type calcium currents in muscle cells.[42](#acn3364-bib-0042){ref-type="ref"} However, neither retigabine nor verapamil applied separately had significant activity in this model, suggesting that either these effects are synergistic or that other mechanisms underlie the anticonvulsant effects of celecoxib. Furthermore, the unique efficacy of celecoxib in chronic epilepsy is not readily explained by these particular off‐target effects, because compounds with similar agonist/antagonist profiles are also effective in acute models of epilepsy,[43](#acn3364-bib-0043){ref-type="ref"}, [44](#acn3364-bib-0044){ref-type="ref"} whereas celecoxib was not (Fig. [4](#acn3364-fig-0004){ref-type="fig"}B). Other non‐COX2 targets of celecoxib that have been identified in nonneuronal models[45](#acn3364-bib-0045){ref-type="ref"} may be relevant to its efficacy in chronic epilepsy. An interesting possible mechanism is suggested by the finding that the effects of COX2 antagonists can be substrate‐specific,[46](#acn3364-bib-0046){ref-type="ref"}, [47](#acn3364-bib-0047){ref-type="ref"} although a celecoxib‐specific substrate has not yet been discovered.

Celecoxib has previously been tested in several epilepsy models with quite mixed results.[48](#acn3364-bib-0048){ref-type="ref"}, [49](#acn3364-bib-0049){ref-type="ref"}, [50](#acn3364-bib-0050){ref-type="ref"}, [51](#acn3364-bib-0051){ref-type="ref"}, [52](#acn3364-bib-0052){ref-type="ref"} The lack of efficacy of other COX2 inhibitors has further dampened enthusiasm for this anticonvulsant strategy.[53](#acn3364-bib-0053){ref-type="ref"} However, our data clarify that celecoxib is only efficacious in chronic epilepsy models, and a review of the prior mixed results also demonstrates that it is effective in in vivo chronic epilepsy models,[48](#acn3364-bib-0048){ref-type="ref"}, [49](#acn3364-bib-0049){ref-type="ref"}, [50](#acn3364-bib-0050){ref-type="ref"} but not acutely evoked seizures.[48](#acn3364-bib-0048){ref-type="ref"}, [51](#acn3364-bib-0051){ref-type="ref"}, [52](#acn3364-bib-0052){ref-type="ref"} We suggest that this may be a signature of a compound that would be effective for the one‐third of epilepsy patients who do not respond to currently available anticonvulsants, all of which were discovered by screening against acutely evoked seizures.

Identification of drugs that prevent or modify epileptogenesis and the progression of epilepsy is an important goal in epilepsy research.[2](#acn3364-bib-0002){ref-type="ref"}, [54](#acn3364-bib-0054){ref-type="ref"} The investigation of drug effects on epileptogenesis is relatively straightforward in the first stage of our pipeline. However, there are important caveats. Most anticonvulsants had modest effects (\<1.65 standard deviations) on biomarkers of seizure activity and cell death in the in vitro screen (Fig. [2](#acn3364-fig-0002){ref-type="fig"}F). Phenytoin had the most robust effects of the tested anticonvulsants, but resistance eventually developed (Fig. [3](#acn3364-fig-0003){ref-type="fig"}C and previous results[30](#acn3364-bib-0030){ref-type="ref"}), as occurs after human brain injury.[55](#acn3364-bib-0055){ref-type="ref"} Thus, many drugs with robust anticonvulsant but not antiepileptogenic effects would be missed in this screen. This suggests that the current screen is an adjunct to, not a replacement of, current anticonvulsant screening methods. The second caveat is that while the lead compound celecoxib inhibited epilepsy for as long as the duration of the experiment without development of resistance (Figs. [3](#acn3364-fig-0003){ref-type="fig"}C and [5](#acn3364-fig-0005){ref-type="fig"}), this effect washed out immediately when drug was removed (Fig. [4](#acn3364-fig-0004){ref-type="fig"}H and I). Thus, the in vitro data indicate that this drug is not antiepileptogenic (i.e., it does not prevent the development of epilepsy). Rather the in vitro data indicate that it is an anticonvulsant that is effective in conditions where other anticonvulsants fail; that is, during the development of epilepsy after brain trauma.[56](#acn3364-bib-0056){ref-type="ref"}

The only discrepancy between the three stages of evaluation regards the apparent antiepileptogenic effect of celecoxib. Chronic, continuous application of 10 *μ*mol/L celecoxib in vitro provided no evidence of an antiepileptogenic effect upon wash‐out (Fig. [4](#acn3364-fig-0004){ref-type="fig"}H). However, a potential antiepileptogenic effect was observed in vivo following single doses administered PO at 6‐day intervals (Fig. [5](#acn3364-fig-0005){ref-type="fig"}B). Whether this is an effect of dosing interval or in vivo metabolism to an antiepileptogenic metabolite will require additional testing.

In the first‐stage in vitro screening, the compressed time course of epileptogenesis and ease of monitoring biochemical biomarkers of seizures during drug application and wash‐out allowed us to determine that celecoxib has an anticonvulsant (but not antiepileptogenic effect) in this model in \<5 weeks. In contrast, antiepileptogenic screening in animal models of chronic epilepsy can take several months.[57](#acn3364-bib-0057){ref-type="ref"}, [58](#acn3364-bib-0058){ref-type="ref"} The second stage of screening was also accomplished in a matter of weeks. The final, in vivo stage of screening was by far the most labor‐intensive, requiring at least 2 months to develop chronic epilepsy with an adequate seizure rate after kainate treatment,[9](#acn3364-bib-0009){ref-type="ref"} 2 months to execute the crossover trial, and several months to analyze the electrographic data with blind procedures. The speed of the first stage can be further enhanced by parallelization, so that this staged analysis could also be applied to medicinal chemistry optimization of lead compounds.
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**Figure S1.** Lactate and LDH in cultures after different concentrations of celecoxib were applied starting from DIV 3. Results are presented in cumulative form (DIV 6, DIV 6 + 11, DIV 6 + 11 + 14, etc.). Note toxicity of 100 *μ*mol/L celecoxib indicated by higher LDH release on DIV 6 (3 days after celecoxib application). Each point is an average of results from *n* = 3 cultures.
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Click here for additional data file.

###### 

**Table S1.** Results of the screen, organized in alphabetical order. Each drug‐concentration pair has been applied to three slice cultures, and compared to three vehicle‐treated slice cultures. Duplicate drug‐concentration pairs represent repeated experiments.

###### 

Click here for additional data file.
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